{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023035","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.895740+00:00","generated_at":"2026-06-11T17:05:05.143632+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AcelRx Q2 net loss $4.4M; raises $10M in private placement; Niyad EUA pending","bullets":["Net loss attributable to common shareholders $4.4M ($0.40/share) vs net income $63.2M in Q2 2022.","Cash and cash equivalents $7.4M at June 30; proforma $17.4M after July private placement.","Closed $10M private placement led by Nantahala Capital, with potential $16.3M from warrants tied to milestones.","EUA for Niyad (nafamostat mesylate) submitted to FDA in April; responses awaited. Registrational study to start Q4 2023.","DSUVIA divested to Alora in April; AcelRx receives 15% royalty on commercial sales, 75% on DoD sales, up to $116.5M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023035","json":"https://secwatch.observer/filing/0001437749-23-023035.json","markdown":"https://secwatch.observer/filing/0001437749-23-023035.md","text":"https://secwatch.observer/filing/0001437749-23-023035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/0001437749-23-023035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/acrx20230809_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:05:05.143632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73a0dd90780ba0202238e29bbc7cec172a697f39","claim":"TALPHERA, INC. reported the three months ended June 30, 2023 results: revenue $0.3 million, net income $4.4 million, EPS $0.40 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"Information ● The cash and cash equivalents balance was $7.4 million as of June 30, 2023. The senior debt with Oxford was fully repaid in the second quarter. ● Revenues of $0.3 million for the second quarter primarily represents the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/0001437749-23-023035-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$4.4 million"},{"label":"EPS","value":"$0.40 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}